Diabetic Retinopathy, Glaucoma, Neovascular
Conditions
Brief summary
To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of postvitrectomy diabetic vitreous hemorrhage (PDVH) accompanied by neovascular glaucoma (NVG) as a means of preventing recurrent vitreous hemorrhage （VH） and optimizing postoperative intraocular pressure（IOP）control.
Interventions
DRUGranibizumab
Sponsors
Ningbo University
Ruijin Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age≥18 years * PDVH obscuring the disc and vessels for more than 14 days and no evidence of retinal detachment after primary vitrectomy for PDR-related complications such as nonclearing VH, macula-involving or macula-threatening tractional retinal detachment, or fibrovascular proliferation with vitreoretinal adhesions * NVG occurred following PDVH less than 4 weeks (NVG was diagnosed when an IOP elevation of 22mmHg or more was accompanied by neovascularization of the iris and/or the anterior chamber angle)
Exclusion criteria
* intraoperative use of long-acting gas or silicone oil in primary vitrectomy, repeat vitrectomy after primary vitrectomy for retinal diseases other than VH, previous history of vitrectomy * previous intravitreal injection of ranibizumab or bevacizumab in either eye * previous intravitreal corticosteroids injection in either eye * pregnancy or current oral contraceptive intake * usage of clopidogrel bisulfate or coumadin * uncontrolled hypertension and cardiac disease * uncontrolled renal or liver disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| vitreous hemorrhage | 12 months |
| intraocular pressure | 12 months |
Outcome results
None listed